switched from 2.5mg to 10mg and the early fullness got better, not worse
Trying to settle this properly because the thread from last year went in circles. The claim: glucagon matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 8 months without either producing anything. What would actually settle it is 27 people measuring the same…
Which trial arm and what was the n?
triple agonism plus glucagon is a different physiological state than GIP/GLP-1 dual
[deleted]
What was the dosing schedule in that arm?
the dosing is steep, the the food-noise thing reports are real, and nobody knows the human safety yet
the dosing is steep, the the food-noise thing reports are real, and nobody knows the human safety yet
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
phase 2 numbers are not maintenance numbers, cite the trial
Dose escalation on retatrutide is steeper and faster than on semaglutide. Do not assume the titration patterns transfer.
Dose escalation on retatrutide is steeper and faster than on semaglutide.
Disagree on that part. 98.4% and 98.3% on the same vial is normal.
Yeah, phase 2 retatrutide is interesting but it is not comparable to phase 3 compounds.